Treatment with IDegAsp was superior in lowering fasting PG ( ETD -1.14 mmol/L [ 95 % CI -1.53 to -0.76 ] , P < 0.001 ) and had a significantly lower final mean daily insulin dose ( estimated rate ratio 0.89 [ 95 % CI 0.83-0 .96 ] , P = 0.002 ) .